European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidosis - other nervous system drugs - vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - tafamidis - capsule - 20mg

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - tafamidis as meglumine - capsules soft gelatin - tafamidis as meglumine 12.2 mg - tafamidis - for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - tafamidis - capsules soft gelatin - tafamidis 61 mg - tafamidis - vyndamax is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - tafamidis - capsule - tafamidis 61.0 mg

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - tafamidis 12.2mg eqv tafamidis meglumine - capsule - tafamidis 12.2mg eqv tafamidis meglumine 20mg

Canada - English - Health Canada

pfizer canada ulc - tafamidis meglumine - capsule - 20mg - tafamidis meglumine 20mg - miscellaneous cardiac drugs

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer inc, united states - tafamidis - capsule, soft - 61 mg

Canada - English - Health Canada

pfizer canada ulc - tafamidis - capsule - 61mg - tafamidis 61mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - tafamidis -